US equities
|
MU
$983.23
▲+5.86%
META
$612.49
▼-1.24%
GOOGL
$324.89
▲+1.34%
NVDA
$215.38
▼-1.17%
MSFT
$531.01
▼-0.06%
TSLA
$404.22
▼-0.80%
SPCX
$145.23
▼-2.25%
SNDK
$1,404.77
▲+7.66%
MU
$983.23
▲+5.86%
META
$612.49
▼-1.24%
GOOGL
$324.89
▲+1.34%
NVDA
$215.38
▼-1.17%
MSFT
$531.01
▼-0.06%
TSLA
$404.22
▼-0.80%
SPCX
$145.23
▼-2.25%
SNDK
$1,404.77
▲+7.66%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
MorphoSys AG - American Depositary Shares
(NQ:
MOR
)
18.96
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about MorphoSys AG - American Depositary Shares
< Previous
1
2
3
4
Next >
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
August 27, 2024
Via
ACCESSWIRE
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI on Behalf of Shareholders
July 17, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
July 12, 2024
From
MorphoSys AG
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DM, SHCR, MOR, ALE on Behalf of Shareholders
July 08, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
March 07, 2024
Via
ACCESSWIRE
MorphoSys AG (NASDAQ: MOR) Near the Top of Equities by Percentage Gain on 2/5
February 05, 2024
Via
Investor Brand Network
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALLG, MOR, BEST, MGOL on Behalf of Shareholders
June 29, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
MOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to Shareholders
June 20, 2024
From
Halper Sadeh LLC
Via
Business Wire
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
June 20, 2024
From
MorphoSys AG
Via
Business Wire
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
June 19, 2024
Via
ACCESSWIRE
MorphoSys AG (NASDAQ: MOR) Leading the Way in Monday Trading Based on Percentage Gain
December 11, 2023
Via
Investor Brand Network
Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
November 09, 2023
Via
ACCESSWIRE
MorphoSys AG Reports First Quarter 2024 Financial Results
April 29, 2024
From
MorphoSys AG
Via
Business Wire
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
April 24, 2024
Via
ACCESSWIRE
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
April 11, 2024
From
MorphoSys AG
Via
Business Wire
MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
April 11, 2024
Via
ACCESSWIRE
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
March 21, 2024
Via
ACCESSWIRE
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 13, 2024
From
MorphoSys AG
Via
Business Wire
MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
February 05, 2024
Via
ACCESSWIRE
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
January 29, 2024
Via
ACCESSWIRE
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 07, 2024
Via
ACCESSWIRE
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
December 10, 2023
From
MorphoSys AG
Via
Business Wire
Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
November 20, 2023
Via
ACCESSWIRE
MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
November 20, 2023
From
MorphoSys AG
Via
Business Wire
MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
November 15, 2023
From
MorphoSys AG
Via
Business Wire
MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
November 02, 2023
Via
ACCESSWIRE
MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
October 25, 2023
Via
ACCESSWIRE
MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
September 12, 2023
Via
ACCESSWIRE
MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results
August 09, 2023
From
MorphoSys AG
Via
Business Wire
MorphoSys AG Reports First Quarter 2023 Financial Results
May 03, 2023
From
MorphoSys AG
Via
Business Wire
< Previous
1
2
3
4
Next >
